Connect with us

Markets

PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category

Published

on

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advocacy organizations around the world who are committed to developing innovative and sustaining programs that help address the unmet needs of the rare disease community. This year, a new entry category dedicated to supporting programs that focus on the transition of those living with Duchenne from adolescence to adulthood has been introduced.

“The new award category recognizes the recent progressions seen in the treatment and management of Duchenne, with many individuals now living longer, fulfilled lives as adults – a milestone that seemed unachievable just a few years ago,” said Mary Frances Harmon, Senior Vice President, Corporate Relations, PTC Therapeutics. “However, this improvement in care creates new challenges, and guidance and support from local organizations will be critical to helping these individuals smoothly navigate the transition to adulthood.”

Until recently, children with Duchenne did not usually live beyond their teens.However, improvements in cardiac and respiratory care mean that life expectancy is increasing, with many Duchenne patients now reaching their 30s and 40s.1,2 As a result of this, there is an increasing emphasis on quality of life and psychosocial support for the Duchenne community, meaning there is an urgent need to coordinate and improve the transition from childhood to adulthood.3

Since inception, the STRIVE program has supported over 30 patient initiatives from not-for-profit organizations around the world. Winning programs have improved access to diagnosis and treatment; created career opportunities for adults with Duchenne; raised awareness of Duchenne in educational, public and healthcare settings; and provided emotional and physical support to caregivers. Further details of all previous winning programs, as well as interviews with last year’s winners discussing the impact of the STRIVE Award on their organization and local community, can be found here.

The deadline for submissions is March 15, and eligible organizations can submit their proposals through an application form available here. Winners will be announced in September 2021.

About the STRIVE Awards Program

PTC began the Strategies to Realize Innovation, Vision, and Empowerment (STRIVE) Awards program in 2015 to support initiatives that benefit the Duchenne community by increasing awareness, diagnosis and education and fostering the development of future patient advocates. Each year, an independent panel of external experts with knowledge in rare diseases, patient advocacy and funding initiatives, judge the entries for innovation, vision and empowerment.

For further information about the program and previous recipients, as well as guidance and support with writing grant entries, please visit the STRIVE section of the PTC website.

About Duchenne Muscular Dystrophy

Primarily affecting males, Duchenne muscular dystrophy (Duchenne) is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk as early as age ten, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and twenties.

More information regarding Duchenne is available through the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy. Additionally, information and resources are available at www.duchenneandyou.com

About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us on www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

For More Information:

Media & Investors:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com

Patient Organizations:
Lucia Oliveira
+1 (908) 912-9205 or (866) 282-5873 
STRIVE@ptcbio.com

References

  1. Muscular Dystrophy Association. Duchenne Muscular Dystrophy (DMD). Available at: https://www.mda.org/disease/duchenne-muscular-dystrophy Accessed: December 2020.
  2. National Institute of Neurological Disorders and Stroke. Muscular Dystrophy: Hope Through Research. Available at: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Muscular-Dystrophy-Hope-Through-Research#3171_9 Accessed: December 2020
  3. Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251–267.

SOURCE PTC Therapeutics, Inc.

Related Links

http://www.ptcbio.com

This article appeared first on here.

Continue Reading
Advertisement TRENDING
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets

ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against OrthoPediatrics Corp. – KIDS

Published

on

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of OrthoPediatrics Corp. (NASDAQ: KIDS) resulting from allegations that OrthoPediatrics may have issued materially misleading business information to the investing public.

On December 2, 2020, Culper Research published a report entitled “OrthoPediatrics Corp. (KIDS): Even Channel Stuffing Can’t Save This Company[.]” The report alleged that OrthoPediatrics has “engaged in a channel stuffing scheme that has systematically and significantly overstated revenues.” On this news, the Company’s stock price fell $5.40 per share, or 12%, to close at $39.35 per share on December 3, 2020.

Then on December 14, 2020, Culper Research published a second report entitled “OrthoPediatrics Corp. (KIDS): Pleading the Fifth” in which it concluded that the Company “is a structurally broken business which has relied on nefarious tactics to inflate its reported revenues.”

Rosen Law Firm is preparing a securities lawsuit on behalf of OrthoPediatrics shareholders. If you purchased securities of OrthoPediatrics please visit the firm’s website at http://www.rosenlegal.com/cases-register-2015.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE Rosen Law Firm, P.A.

Related Links

www.rosenlegal.com

This article appeared first on here.

Continue Reading

Markets

University Medical Center Opens Onsite COVID-19 Vaccination Center At Encore At Wynn Las Vegas

Published

on

The UMC COVID-19 Vaccination Center will open its doors at Encore at Wynn Las Vegas (NASDAQ: WYNN) on Monday, January 18.

The UMC COVID-19 Vaccination Center will operate Monday – Friday, with the ability to increase hours as the program expands. It is conveniently located in the resort’s convention space near the Encore self-parking garage. Vaccines at the Center are available to residents of Nevada who are eligible under the current State of Nevada vaccination guidelines.

Initially, the UMC COVID-19 Vaccination Center will only offer the vaccine to people 70 and older, healthcare workers, and first responders.

To ensure efficiency, appointments are required by UMC and can be scheduled in advance at www.umcsn.com/COVIDvaccine or by calling (702) 383-2619. Eligible Nevadans may need to book their appointments several weeks in advance.

To determine eligibility for the vaccine under the current state guidelines, please visit https://nvhealthresponse.nv.gov/wp-content/uploads/2021/01/NEVADA-COVID-19-VACCINE-PLAYBOOK-V3-BRIEF_011121.pdf.

This unique partnership was formed to increase distribution of the vaccine throughout the Las Vegas Valley at a convenient location, and to assist in the state’s recovery from the pandemic.

“We offered Encore as a vaccination location to help facilitate vaccine distribution as quickly and efficiently as possible throughout the Las Vegas Valley,” said Matt Maddox, CEO of Wynn Resorts. “Our partnership with UMC began with our extensive onsite employee testing program. Based upon the success of that program with UMC, we look forward to hosting this critical step in our state’s economic and health recovery.”

“The UMC COVID-19 Vaccination Center at Encore will serve as a valuable asset to our community as we work together to protect our most vulnerable populations and eventually bring an end to the COVID-19 pandemic,” said UMC CEO Mason Van Houweling. “UMC’s world-class health care team members look forward to working alongside our trusted partners at Wynn Resorts to build a brighter, healthier future for Southern Nevada.”

The Encore location will replace UMC’s existing COVID-19 vaccination clinic at UMC’s Delta Point Building. All UMC vaccination appointments scheduled on or after January 18 will take place at the Encore location.

The UMC COVID-19 Vaccination Center is equipped to offer hundreds of vaccinations each day. Additional information is available at www.umcsn.com/COVIDvaccine.

About Wynn Resorts COVID-19 Relief Efforts

Wynn Resorts is committed to protecting our employees, working for the health and safety of our guests, and taking care of our communities impacted by COVID-19 with relief efforts that fill financial and supply chain gaps where they matter most. The donation and volunteer strategies follow an extensive financial protection plan implemented by Wynn Resorts CEO Matt Maddox that began with a $250 million investment that ensured all 15,000 Wynn employees in North America received their full wage during the government-mandated shutdown.

To provide relief to first responders and protection to those suffering the financial impact of the crisis, the Company procured and donated more than $3 million worth of financial aid, personal protective equipment, food and prepared meals, and essential cleaning and hygiene supplies to dozens of health care facilities and local nonprofit organizations throughout Las Vegas and Greater Boston. In May 2020, Wynn Las Vegas began providing all employees with direct access to reliable and accurate COVID-19 tests on-site at no cost; and in early 2021 will debut a custom-built state-of-the-art COVID-19 testing lab and mobile health app available to resort guests.

Media Contact:
Michael Weaver
702-770-7501
michael.weaver@wynnresorts.com

Deanna Pettit-Irestone
702-770-2121
deanna.pettit@wynnlasvegas.com

SOURCE Wynn Las Vegas

Related Links

http://www.wynnlasvegas.com

This article appeared first on here.

Continue Reading

Markets

Caesars Entertainment, Inc. to Report 2020 Fourth Quarter and Full-Year Results on February 25, 2021

Published

on

Caesars Entertainment, Inc. (NASDAQ: CZR) will release its financial results for the fourth quarter and full-year 2020 after the market closes on Thursday, February 25, 2021. The company will also host a conference call on February 25, 2021 at 5:00 p.m. Eastern Time2:00 p.m. Pacific Time, to discuss its results and other matters related to the company.

Participants should dial (833) 665-0647, or (914) 987-7309 for international callers, and enter Conference ID 5039038 approximately 10 minutes before the call start time. The call will be accessible on the Investor Relations section of Caesars Entertainment’s website at https://investor.caesars.com.

A recording of the live call will be available on the Investor Relations section of the company’s website for 90 days after the event.

About Caesars Entertainment, Inc.

Caesars Entertainment, Inc. is one of the largest gaming-entertainment companies in the U.S. and one of the world’s most diversified gaming-entertainment providers. Since its beginning in Reno, Nevada, in 1937, Caesars Entertainment has grown through development of new resorts, expansions and acquisitions. Caesars Entertainment’s resorts operate primarily under the Caesars®, Harrah’s®, Horseshoe® and Eldorado® brand names. Caesars Entertainment offers diversified amenities and one-of-a-kind destinations, with a focus on building loyalty and value with its guests through a unique combination of impeccable service, operational excellence and technology leadership. Caesars Entertainment is committed to its employees, suppliers, communities and the environment through its PEOPLE PLANET PLAY framework. For more information, please visit www.caesars.com/corporate.

SOURCE Caesars Entertainment, Inc.

Related Links

http://www.caesars.com

This article appeared first on here.

Continue Reading
Advertisement

TRENDING

Advertisement

Submit an Article

Send us your details and the subject of your article and an IAM editor will be in touch with you shortly

Trending